{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T09:14:18Z","timestamp":1767172458801,"version":"build-2238731810"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-024-04757-z","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T20:02:28Z","timestamp":1725998548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ibrutinib as treatment for Bing\u2013Neel syndrome reclassified as glioblastoma: a case report"],"prefix":"10.1186","volume":"18","author":[{"given":"Charlotte Dahl","family":"Gravesen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iman","family":"Chanchiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida Bruun","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin Bang","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik Severin Gr\u00e5e","family":"Harbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikke Hedegaard","family":"Dahlrot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"issue":"5","key":"4757_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, et\u00a0al. European organisation for research and treatment of cancer brain tumour and radiation oncology groups; national cancer institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(09)70025-7.","journal-title":"Lancet Oncol"},{"key":"4757_CR2","unstructured":"Diagnostik, udredning og behandling af Lymfoplasmacystisk lymfom\/ Waldenstr\u00f6m\u2019s macroglobulin\u00e6mi, Danske Multidisciplin\u00e6re Cancer Grupper. 2020. https:\/\/www.dmcg.dk\/siteassets\/kliniske-retningslinjer---skabeloner-og-vejledninger\/kliniske-retningslinjer-opdelt-pa-dmcg\/dlg\/dlg_diag_udr_beh_waldenstroms-macro_admgodk260421.pdf. Accessed on 20 Dec 2020."},{"issue":"3","key":"4757_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/bjh.16167","volume":"187","author":"JJ Castillo","year":"2019","unstructured":"Castillo JJ, Treon SP. How we manage Bing-Neel syndrome. Br J Haematol. 2019;187(3):277\u201385. https:\/\/doi.org\/10.1111\/bjh.16167.","journal-title":"Br J Haematol"},{"issue":"374","key":"4757_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1560","volume":"14","author":"C McKinnon","year":"2021","unstructured":"McKinnon C, Nandhabalan M, et\u00a0al. Glioblastoma: clinical presentation, diagnosis, and management. BMJ. 2021;14(374): n1560. https:\/\/doi.org\/10.1136\/bmj.n1560.","journal-title":"BMJ"},{"issue":"12","key":"4757_CR5","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.3324\/haematol.2015.133744","volume":"100","author":"L Simon","year":"2015","unstructured":"Simon L, Fitsiori A, Lema R, et\u00a0al. Bing-Neel syndrome, a rare complication of Waldenstr\u00f6m macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO). Haematologica. 2015;100(12):1587\u201394. https:\/\/doi.org\/10.3324\/haematol.2015.133744.","journal-title":"Haematologica"},{"issue":"5","key":"4757_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/bjh.13883","volume":"172","author":"JJ Castillo","year":"2016","unstructured":"Castillo JJ, D\u2019Sa S, Lunn MP, et\u00a0al. Central nervous system involvement by Waldenstr\u00f6m macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016;172(5):709\u201315. https:\/\/doi.org\/10.1111\/bjh.13883.","journal-title":"Br J Haematol"},{"key":"4757_CR7","unstructured":"CNS-lymfom\u2013diagnostik, behandling, rehabilitering, Dansk Lymfromgruppe. 2020. http:\/\/www.lymphoma.dk\/wp-content\/uploads\/2020\/09\/DLG_CNS-Lymfom_AdmGodk180920.pdf. Accessed on 6 Feb 2020."},{"issue":"4","key":"4757_CR8","doi-asserted-by":"publisher","first-page":"iv41","DOI":"10.1093\/annonc\/mdy146","volume":"29","author":"E Kastritis","year":"2018","unstructured":"Kastritis E, Leblond V, et\u00a0al. ESMO guidelines committee. Waldenstr\u00f6m\u2019s macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(4):iv41\u201350. https:\/\/doi.org\/10.1093\/annonc\/mdy146. (Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv270. Erratum in: Ann Oncol. 2019 May 1;30(5):860-862).","journal-title":"Ann Oncol"},{"issue":"3","key":"4757_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043208","volume":"11","author":"LS Bjorland","year":"2021","unstructured":"Bjorland LS, Fluge O, et\u00a0al. Treatment approach and survival from glioblastoma: results from a population-based retrospective cohort study from Western Norway. BMJ Open. 2021;11(3): e043208. https:\/\/doi.org\/10.1136\/bmjopen-2020-043208.","journal-title":"BMJ Open"},{"issue":"13","key":"4757_CR10","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.3390\/cancers14133161","volume":"14","author":"NF Brown","year":"2022","unstructured":"Brown NF, Ottaviani D, et\u00a0al. Survival outcomes and prognostic factors in glioblastoma. Cancers (Basel). 2022;14(13):3161. https:\/\/doi.org\/10.3390\/cancers14133161.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"4757_CR11","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.3390\/ijms23031711","volume":"23","author":"EN Mathew","year":"2022","unstructured":"Mathew EN, Berry BC, et\u00a0al. Delivering therapeutics to glioblastoma: overcoming biological constraints. Int J Mol Sci. 2022;23(3):1711. https:\/\/doi.org\/10.3390\/ijms23031711.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4757_CR12","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/bjh.16946","volume":"192","author":"KL Lewis","year":"2021","unstructured":"Lewis KL, Chin CK, Manos K, et\u00a0al. Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma alliance\/MD Anderson Cancer Center experience. Br J Haematol. 2021;192(6):1049\u201353. https:\/\/doi.org\/10.1111\/bjh.16946.","journal-title":"Br J Haematol"},{"issue":"2","key":"4757_CR13","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/bjh.14218","volume":"179","author":"C Mason","year":"2017","unstructured":"Mason C, Savona S, Rini JN, et\u00a0al. Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. Br J Haematol. 2017;179(2):339\u201341. https:\/\/doi.org\/10.1111\/bjh.14218.","journal-title":"Br J Haematol"},{"key":"4757_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bjh.18036","volume":"00","author":"G Pratt","year":"2022","unstructured":"Pratt G, El-Sharkawi D, Kothari J, et\u00a0al. Guidelines on the diagnosis and management of Waldenstr\u00f6m macroglobulinaemia\u2014a British society for haematology guideline. Br J Haematol. 2022;00:1\u201317. https:\/\/doi.org\/10.1111\/bjh.18036.","journal-title":"Br J Haematol"},{"issue":"1","key":"4757_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13046-017-0549-6","volume":"36","author":"J Wang","year":"2017","unstructured":"Wang J, Liu X, Hong Y, et\u00a0al. Ibrutinib, a Bruton\u2019s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma. J Exp Clin Cancer Res. 2017;36(1):96. https:\/\/doi.org\/10.1186\/s13046-017-0549-6.","journal-title":"J Exp Clin Cancer Res"},{"issue":"443","key":"4757_CR16","doi-asserted-by":"publisher","first-page":"eaah6816","DOI":"10.1126\/scitranslmed.aah6816","volume":"10","author":"Y Shi","year":"2018","unstructured":"Shi Y, Guryanova OA, Zhou W, et\u00a0al. Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance. Sci Transl Med. 2018;10(443):eaah6816. https:\/\/doi.org\/10.1126\/scitranslmed.aah6816.","journal-title":"Sci Transl Med."},{"issue":"1","key":"4757_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000522239","volume":"14","author":"DM Lewis","year":"2022","unstructured":"Lewis DM, Colchester NTH, Allen D, Nicoll JAR, Katifi HA, Duncombe AS. Glioblastoma, IDH-wildtype: a new association with IgM paraproteinaemic neuropathy? Case Rep Neurol. 2022;14(1):213\u201322. https:\/\/doi.org\/10.1159\/000522239.","journal-title":"Case Rep Neurol."},{"issue":"3","key":"4757_CR18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","volume":"31","author":"MJ van den Bent","year":"2013","unstructured":"van den Bent MJ, Brandes AA, et\u00a0al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344\u201350. https:\/\/doi.org\/10.1200\/JCO.2012.43.2229.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4757_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1212\/wnl.56.1.118","volume":"56","author":"AC Kappelle","year":"2001","unstructured":"Kappelle AC, Postma TJ, et\u00a0al. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology. 2001;56(1):118\u201320. https:\/\/doi.org\/10.1212\/wnl.56.1.118.","journal-title":"Neurology"},{"key":"4757_CR20","unstructured":"TrialX. Chemo-immunotherapy using ibrutinib plus indoximod for patients with pediatric brain cancer, clinical research trial listing (medulloblastoma, primary brain tumor, glioblastoma, ependymoma) (NCT05106296 ) (trialx.com). Accessed 21 June 2024."},{"issue":"1","key":"4757_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/pharmaceutics15010059","volume":"15","author":"HK Brar","year":"2022","unstructured":"Brar HK, Jose J, et\u00a0al. Tyrosine kinase inhibitors for glioblastoma multiforme: challenges and opportunities for drug delivery. Pharmaceutics. 2022;15(1):59. https:\/\/doi.org\/10.3390\/pharmaceutics15010059.","journal-title":"Pharmaceutics"},{"issue":"43","key":"4757_CR22","doi-asserted-by":"publisher","first-page":"69961","DOI":"10.18632\/oncotarget.11572","volume":"7","author":"L Wei","year":"2016","unstructured":"Wei L, Su YK, et\u00a0al. Preclinical investigation of ibrutinib, a Bruton\u2019s kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes. Oncotarget. 2016;7(43):69961\u201375. https:\/\/doi.org\/10.18632\/oncotarget.11572.","journal-title":"Oncotarget"},{"key":"4757_CR23","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1200\/JCO.2023.41.16_suppl.2067","volume":"41","author":"MS Ahluwalia","year":"2023","unstructured":"Ahluwalia MS, et\u00a0al. Phase I study of BTK inhibitor ibrutinib with temozolomide and radiation in newly-diagnosed glioblastoma (EQUILIBRIUM): final trial report. J Clinic Oncol. 2023;41:2067\u20132067. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.2067.","journal-title":"J Clinic Oncol."}],"updated-by":[{"DOI":"10.1186\/s13256-025-05494-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000}}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04757-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-024-04757-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04757-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T05:29:10Z","timestamp":1755667750000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-024-04757-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4757"],"URL":"https:\/\/doi.org\/10.1186\/s13256-024-04757-z","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"28 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13256-025-05494-7","URL":"https:\/\/doi.org\/10.1186\/s13256-025-05494-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"424"}}